Khan K.H.,GI and Lymphoma Unit |
Yap T.A.,The Royal Marsden NHS Foundation Trust |
Yan L.,Merck And Co. |
Yan L.,Peking University |
Cunningham D.,GI and Lymphoma Unit
Chinese Journal of Cancer | Year: 2013
The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer and is important for tumor cell growth and survival. The development of targeted therapies against mTOR, a vital substrate along this pathway, led to the approval of allosteric inhibitors, including everolimus and temsirolimus, for the treatment of breast, renal, and pancreatic cancers. However, the suboptimal duration of response in unselected patients remains an unresolved issue. Numerous novel therapies against critical nodes of this pathway are therefore being actively investigated in the clinic in multiple tumour types. In this review, we focus on the progress of these agents in clinical development along with their biological rationale, the need of predictive biomarkers and various combination strategies, which will be useful in counteracting the mechanisms of resistance to this class of drugs.
Tarazona N.,GI and Lymphoma Unit |
Navarro L.,University of Valencia |
Cejalvo J.M.,University of Valencia |
Gambardella V.,University of Valencia |
And 4 more authors.
OncoTargets and Therapy | Year: 2015
Ewing’s sarcoma is a rare and highly aggressive cancer most frequently arising in people under 20 years of age. We report an uncommon case of primary paraesophageal Ewing’s sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor. The patient was totally refractory to chemotherapy and died 17 months after diagnosis. We underscore the need for better understanding of the molecular pathogenesis of the disease and improved systemic therapy options. © 2015 Tarazona et al.